Andrew Neuschatz, MD
Radiation Oncology · Tucson, AZNPI 1124077185
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $758 and has fallen 59.4% since, to $308 in 2025. That places this record below the midpoint for radiation oncology clinicians in AZ, where the typical reported total is $1,482.
Across 64 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$166
- Novartis$136
- Bayer$130
- AstraZeneca$93
- Johnson & Johnson$86
- Regeneron Healthcare Solutions, Inc.$86
- plus $785 from 24 others
What the payments were for
- Food & beverage$1,482100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $166 |
| Novartis | 6 | $136 |
| Bayer | 6 | $130 |
| AstraZeneca | 4 | $93 |
| Johnson & Johnson | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| AbbVie | 3 | $73 |
| Blueprint Medicines Corporation | 3 | $67 |
| Pinnacle Biologics, Inc | 1 | $61 |
| Genentech USA, Inc. | 2 | $53 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Sobi, Inc | 2 | $43 |
| Pfizer | 2 | $37 |
| Tersera Therapeutics LLC | 1 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Novocure Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Genmab U.S., Inc. | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Reflexion Medical, Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Seagen Inc. | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $14 |
How this compares
$1,482 in reported general payments places this provider in the 50th percentile of 138 radiation oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 15 | $373 |
| SsdSilver Sulfadiazine | 14 | $182 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Tucson
- Baldassarre SteaTucson$10K
- Robert GinTucson$9K
- Curtis MackTucson$8K
- David VonkTucson$6K
- Christopher MorrisonTucson$4K
- Samuel DayTucson$3K
- David FryeTucson$3K
- Reginald WestmacottTucson$3K
- Sarah KilicTucson$2K
- John KreslPhoenix$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.